Zhejiang Wecome Pharmaceutical Company Limited (SHE:300878)
34.45
+0.66 (1.95%)
Jul 15, 2026, 3:04 PM CST
SHE:300878 Revenue
Zhejiang Wecome Pharmaceutical Company had revenue of 69.66M CNY in the quarter ending March 31, 2026, a decrease of -0.16%. This brings the company's revenue in the last twelve months to 225.16M, up 1.87% year-over-year. In the year 2025, Zhejiang Wecome Pharmaceutical Company had annual revenue of 225.27M, down -35.86%.
Revenue (ttm)
225.16M
Revenue Growth
+1.87%
P/S Ratio
21.32
Revenue / Employee
420.86K
Employees
535
Market Cap
4.80B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 225.27M | -125.93M | -35.86% |
| Dec 31, 2024 | 351.20M | -168.42M | -32.41% |
| Dec 31, 2023 | 519.62M | -12.82M | -2.41% |
| Jan 1, 2023 | 532.44M | -100.51M | -15.88% |
| Jan 1, 2022 | 632.95M | 10.19M | 1.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Suzhou Fengbei Biotech Stock | 3.61B |
| Novogene | 2.26B |
| Wuhan Hvsen Biotechnology | 1.74B |
| Hefei Lifeon Pharmaceutical | 1.55B |
| Shenzhen Weiguang Biological Products | 1.26B |
| ChemPartner PharmaTech | 1.14B |
| Beijing Konruns Pharmaceutical | 917.99M |
| R&G PharmaStudies | 896.26M |